OPRX OptimizeRx CorpcompanySEC Filings & Insider Trading Activity 2026
Latest OptimizeRx Corp (OPRX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on April 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for OptimizeRx Corp (OPRX) (SEC CIK 1448431), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Maturity extended 2 years to Oct 11, 2029, reducing near-term refinancing risk
- • Share buyback authorized up to $10M, permitted through Mar 15, 2027 — signals management confidence in valuation
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 results reported; detailed figures in Exhibit 99.1 press release
- • New $10M share repurchase program announced alongside earnings — signals management confidence in valuation
Item 8.01: Other Events
- • Board authorized $10M share buyback program, effective March 12, 2026, expiring March 15, 2027 or upon full utilization
- • Repurchases funded via existing cash/cash equivalents — no new debt or dilution implied
Recent 8-K FilingsCurrent Reports
AI-powered analysis of OptimizeRx Corp (OPRX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 9, 2026 | — | — | — |
8-K | Mar 30, 2026 | — | — | — |
10-K | Mar 12, 2026 | Dec 31, 2025 | — | |
8-K | Mar 5, 2026 | — | Analysis | — |
10-Q | Nov 7, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 8, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 20, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 15, 2024 | Jun 30, 2024 | — | |
10-Q | May 15, 2024 | Mar 31, 2024 | — | |
10-K | Apr 15, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 14, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 12, 2023 | Mar 31, 2023 | — | |
10-K | Mar 10, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Mar 8, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 9, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest OPRX SEC filings in 2026?
OptimizeRx Corp (OPRX) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did OPRX file its most recent 10-K annual report?
OptimizeRx Corp (OPRX) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view OPRX 10-Q quarterly reports?
OptimizeRx Corp (OPRX)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every OPRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has OPRX filed recently?
OptimizeRx Corp (OPRX)'s most recent 8-K was filed on April 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find OPRX insider trading activity (Form 4)?
SignalX aggregates every OPRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does OPRX file with the SEC?
OptimizeRx Corp (OPRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new OPRX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for OptimizeRx Corp (OPRX).
What is OPRX's SEC CIK number?
OptimizeRx Corp (OPRX)'s SEC CIK (Central Index Key) number is 1448431. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1448431 to look up all OPRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find OPRX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from OptimizeRx Corp (OPRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of OptimizeRx Corp SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 72+ filings.